{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:02:10Z","timestamp":1792785730192,"version":"4.5.0"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002878","name":"Junta de Andaluc\u00eda","doi-asserted-by":"publisher","award":["FQM-7316"],"award-info":[{"award-number":["FQM-7316"]}],"id":[{"id":"10.13039\/501100002878","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Spanish Ministerio de Econom\u00eda y Competitividad","award":["SAF2014-58354-R"],"award-info":[{"award-number":["SAF2014-58354-R"]}],"id":[{"id":"https:\/\/ror.org\/01txxn211","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002924","name":"FEDER","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"name":"EU"},{"DOI":"10.13039\/501100002878","name":"Junta de Andaluc\u00eda","doi-asserted-by":"publisher","award":["FQM-7316"],"award-info":[{"award-number":["FQM-7316"]}],"id":[{"id":"10.13039\/501100002878","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Juan de la Cierva Fellowship"},{"name":"Spanish Ministerio de Econom\u00eda y Competitividad","id":[{"id":"https:\/\/ror.org\/01txxn211","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.ejmech.2018.01.037","type":"journal-article","created":{"date-parts":[[2018,1,16]],"date-time":"2018-01-16T21:22:32Z","timestamp":1516137752000},"page":"123-138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"special_numbering":"C","title":["Alkylated resveratrol prodrugs and metabolites as potential therapeutics for neurodegenerative diseases"],"prefix":"10.1016","volume":"146","author":[{"given":"Pablo","family":"Pe\u00f1alver","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9327-6182","authenticated-orcid":false,"given":"Efres","family":"Belmonte-Reche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norma","family":"Ad\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Caro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Luisa","family":"Mateos-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Gonz\u00e1lez-Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2400-405X","authenticated-orcid":false,"given":"Juan Carlos","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 3","key":"10.1016\/j.ejmech.2018.01.037_bib1","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.3233\/JAD-132738","article-title":"Apoptosis and oxidative stress in neurodegenerative diseases","volume":"42","author":"Radi","year":"2014","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.ejmech.2018.01.037_bib2","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nature05292","article-title":"Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases","volume":"443","author":"Lin","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2018.01.037_bib3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.biopha.2015.07.025","article-title":"Oxidative stress, mitochondrial dysfunction and neurodegenerative diseases; a mechanistic insight","volume":"74","author":"Bhat","year":"2015","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2018.01.037_bib4","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jns.2012.05.030","article-title":"Mitochondria, oxidative stress and neurodegeneration","volume":"322","author":"Federico","year":"2012","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.ejmech.2018.01.037_bib5","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/imm.12233","article-title":"Inflammation in neurodegenerative diseases\u2013an update","volume":"142","author":"Amor","year":"2014","journal-title":"Immunology"},{"key":"10.1016\/j.ejmech.2018.01.037_bib6","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1021\/jm058225d","article-title":"Designed multiple ligands. An emerging drug discovery paradigm","volume":"48","author":"Morphy","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.037_bib7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drudis.2006.11.008","article-title":"Multi-target therapeutics: when the whole is greater than the sum of the parts","volume":"12","author":"Zimmermann","year":"2007","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2018.01.037_bib8","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.drudis.2014.08.006","article-title":"Multi-target approach for natural products in inflammation","volume":"19","author":"Koeberle","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2018.01.037_bib9","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.2174\/0929867321666140303144625","article-title":"Multi-target drug design approaches for multifactorial diseases: from neurodegenerative to cardiovascular applications","volume":"21","author":"Katselou","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.037_bib10","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.2174\/0929867311320130007","article-title":"Multi-target compounds acting in the central nervous system designed from natural products","volume":"20","author":"Chen","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.037_bib11","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.bbadis.2014.10.016","article-title":"Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases","volume":"1852","author":"Zordoky","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2018.01.037_bib12","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd2060","article-title":"Therapeutic potential of resveratrol: the in\u00a0vivo evidence","volume":"5","author":"Baur","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2018.01.037_bib13","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1126\/science.275.5297.218","article-title":"Cancer chemopreventive activity of resveratrol, a natural product derived from grapes","volume":"275","author":"Jang","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2018.01.037_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10753-006-9012-0","article-title":"Effects of resveratrol in inflammatory arthritis","volume":"30","author":"Elmali","year":"2007","journal-title":"Inflammation"},{"key":"10.1016\/j.ejmech.2018.01.037_bib15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.neuint.2015.08.009","article-title":"Resveratrol neuroprotection in stroke and traumatic CNS injury","volume":"89","author":"Lopez","year":"2015","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ejmech.2018.01.037_bib16","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.bbadis.2014.09.011","article-title":"Neuroprotective action of resveratrol","volume":"1852","author":"Bastianetto","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2018.01.037_bib17","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1021\/cn400094w","article-title":"Neuroprotective properties and mechanisms of resveratrol in in\u00a0vitro and in\u00a0vivo experimental cerebral stroke models","volume":"4","author":"Singh","year":"2013","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2018.01.037_bib18","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/nyas.12796","article-title":"Direct molecular targets of resveratrol: identifying key interactions to unlock complex mechanisms","volume":"1348","author":"Britton","year":"2015","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejmech.2018.01.037_bib19","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.bbadis.2014.10.005","article-title":"The molecular targets of resveratrol","volume":"1852","author":"Kulkarni","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2018.01.037_bib20","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1212\/WNL.0000000000002035","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease","volume":"85","author":"Turner","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.ejmech.2018.01.037_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-016-0779-0","article-title":"Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer's disease","volume":"14","author":"Moussa","year":"2017","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.ejmech.2018.01.037_bib22","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jnutbio.2009.02.004","article-title":"Protective effects of pinostilbene, a resveratrol methylated derivative, against 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells","volume":"21","author":"Chao","year":"2010","journal-title":"J.\u00a0Nutr. Biochem."},{"key":"10.1016\/j.ejmech.2018.01.037_bib23","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/j.neurobiolaging.2011.08.015","article-title":"Low-dose pterostilbene, but not resveratrol, is a potent neuromodulator in aging and Alzheimer's disease","volume":"33","author":"Chang","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.ejmech.2018.01.037_bib24","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.bmc.2010.11.018","article-title":"New hydroxystilbenoid derivatives endowed with neuroprotective activity and devoid of interference with estrogen and aryl hydrocarbon receptor-mediated transcription","volume":"19","author":"Villalonga-Barber","year":"2011","journal-title":"Bioorg. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2018.01.037_bib25","first-page":"665","article-title":"Semisynthesis and biological evaluation of prenylated resveratrol derivatives as multi-targeted agents for Alzheimer's disease","volume":"71","author":"Puksasook","year":"2017","journal-title":"J.\u00a0Nat. Med."},{"key":"10.1016\/j.ejmech.2018.01.037_bib26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejmech.2013.10.068","article-title":"Design, synthesis and biological evaluation of imine resveratrol derivatives as multi-targeted agents against Alzheimer's disease","volume":"71","author":"Li","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.037_bib27","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ejmech.2016.12.048","article-title":"Tacrine-resveratrol fused hybrids as multi-target-directed ligands against Alzheimer's disease","volume":"127","author":"Jerabek","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.037_bib28","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.1021\/jm400567s","article-title":"Design, synthesis, and evaluation of multitarget-directed resveratrol derivatives for the treatment of Alzheimer's disease","volume":"56","author":"Lu","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.037_bib29","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.2174\/1871520614666140627150054","article-title":"Improving the efficacy of plant polyphenols","volume":"14","author":"Biasutto","year":"2014","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1016\/j.ejmech.2018.01.037_bib30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/nyas.13401","article-title":"Resveratrol derivatives as a pharmacological tool","volume":"1403","author":"Biasutto","year":"2017","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejmech.2018.01.037_bib31","doi-asserted-by":"crossref","first-page":"7365","DOI":"10.1021\/jm1007006","article-title":"Preventive oral treatment with resveratrol pro-prodrugs drastically reduce colon inflammation in rodents","volume":"53","author":"Larrosa","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.037_bib32","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ejmech.2015.04.038","article-title":"Synthesis of amphiphilic resveratrol lipoconjugates and evaluation of their anticancer activity towards neuroblastoma SH-SY5Y cell line","volume":"96","author":"Chillemi","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.037_bib33","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.brainresbull.2011.09.021","article-title":"Polydatin modulates inflammation by decreasing NF-kappaB activation and oxidative stress by increasing Gli1, Ptch1, SOD1 expression and ameliorates blood-brain barrier permeability for its neuroprotective effect in pMCAO rat brain","volume":"87","author":"Ji","year":"2012","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.ejmech.2018.01.037_bib34","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S0140-6736(88)91691-1","article-title":"Analgesic activity of morphine-6-glucuronide","volume":"1","author":"Osborne","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2018.01.037_bib35","doi-asserted-by":"crossref","first-page":"5033","DOI":"10.1021\/jm100274c","article-title":"Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites","volume":"53","author":"Hoshino","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.037_bib36","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/cbic.201600084","article-title":"Cytotoxic, antiangiogenic and antitelomerase activity of glucosyl- and acyl- resveratrol prodrugs and resveratrol sulfate metabolites","volume":"17","author":"Falomir","year":"2016","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2018.01.037_bib37","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1021\/np0303153","article-title":"Resveratrol derivatives and their role as potassium channels modulators","volume":"67","author":"Orsini","year":"2004","journal-title":"J.\u00a0Nat. Prod."},{"key":"10.1016\/j.ejmech.2018.01.037_bib38","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.neuint.2015.07.017","article-title":"Effects of pterostilbene and resveratrol on brain and behavior","volume":"89","author":"Poulose","year":"2015","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ejmech.2018.01.037_bib39","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1021\/cn400094w","article-title":"Neuroprotective properties and mechanisms of resveratrol in in\u00a0vitro and in\u00a0vivo experimental cerebral stroke models","volume":"4","author":"Singh","year":"2013","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2018.01.037_bib40","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/0306-4522(95)00108-U","article-title":"A\u00a0detailed analysis of hydrogen peroxide-induced cell death in primary neuronal culture","volume":"67","author":"Whittemore","year":"1995","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejmech.2018.01.037_bib41","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.phrs.2017.08.002","article-title":"Anti-inflammatory activity of natural stilbenoids: a review","volume":"124","author":"Dvorakova","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2018.01.037_bib42","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neuint.2015.10.011","article-title":"Novel promising therapeutics against chronic neuroinflammation and neurodegeneration in Alzheimer's disease","volume":"95","author":"Venigalla","year":"2016","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ejmech.2018.01.037_bib43","doi-asserted-by":"crossref","first-page":"318","DOI":"10.2174\/1389201015666140617101332","article-title":"Resveratrol as a protective molecule for neuroinflammation: a review of mechanisms","volume":"15","author":"Renaud","year":"2014","journal-title":"Curr. Pharmaceut. Biotechnol."},{"key":"10.1016\/j.ejmech.2018.01.037_bib44","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/bdrc.20214","article-title":"Zebrafish: as an integrative model for twenty-first century toxicity testing","volume":"93","author":"Sipes","year":"2011","journal-title":"Birth Defects Res C Embryo Today"},{"key":"10.1016\/j.ejmech.2018.01.037_bib45","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.yrtph.2014.05.018","article-title":"OECD validation study to assess intra- and inter-laboratory reproducibility of the zebrafish embryo toxicity test for acute aquatic toxicity testing","volume":"69","author":"Busquet","year":"2014","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.01.037_bib46","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1212\/WNL.28.4.325","article-title":"Specific antagonism of GABA-mediated postsynaptic inhibition in cultured mammalian spinal cord neurons: a common mode of convulsant action","volume":"28","author":"Macdonald","year":"1978","journal-title":"Neurology"},{"key":"10.1016\/j.ejmech.2018.01.037_bib47","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S0022-3565(24)29466-0","article-title":"Pentylenetetrazole-induced inhibition of recombinant gamma-aminobutyric acid type A (GABA(A)) receptors: mechanism and site of action","volume":"298","author":"Huang","year":"2001","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2018.01.037_bib48","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s11055-006-0082-0","article-title":"Pentylenetetrazol kindling in rats: is neurodegeneration associated with manifestations of convulsive activity?","volume":"36","author":"Pavlova","year":"2006","journal-title":"Neurosci. Behav. Physiol."},{"key":"10.1016\/j.ejmech.2018.01.037_bib49","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.neulet.2005.09.021","article-title":"Pentylenetetrazole kindling induces neuronal cyclin B1 expression in rat hippocampus","volume":"392","author":"Pavlova","year":"2006","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejmech.2018.01.037_bib50","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.neuroscience.2006.02.076","article-title":"Repeated brief epileptic seizures by pentylenetetrazole cause neurodegeneration and promote neurogenesis in discrete brain regions of freely moving adult rats","volume":"140","author":"Park","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejmech.2018.01.037_bib51","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.biopha.2016.09.048","article-title":"Anticonvulsant and neuroprotective effects of apelin-13 on pentylenetetrazole-induced seizures in male rats","volume":"84","author":"Kalantaripour","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2018.01.037_bib52","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/npp.2010.104","article-title":"Modes and models of forebrain cholinergic neuromodulation of cognition","volume":"36","author":"Hasselmo","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejmech.2018.01.037_bib53","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/sj.bjp.0704719","article-title":"Caprylic acid and medium-chain triglycerides inhibit IL-8 gene transcription in Caco-2 cells: comparison with the potent histone deacetylase inhibitor trichostatin A","volume":"136","author":"Hoshimoto","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.01.037_bib54","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1177\/0148607113489833","article-title":"Impact of short- and medium-chain fatty acids on mitochondrial function in severe inflammation","volume":"38","author":"Hecker","year":"2014","journal-title":"JPEN - J. Parenter. Enter. Nutr."},{"key":"10.1016\/j.ejmech.2018.01.037_bib55","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1212\/WNL.21.11.1097","article-title":"Medium-chain triglycerides as a therapy for intractable childhood epilepsy","volume":"21","author":"Huttenlocher","year":"1971","journal-title":"Neurology"},{"key":"10.1016\/j.ejmech.2018.01.037_bib56","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1136\/adc.61.12.1168","article-title":"The medium chain triglyceride diet and intractable epilepsy","volume":"61","author":"Sills","year":"1986","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.ejmech.2018.01.037_bib57","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.neuroscience.2007.03.001","article-title":"Induction of neurite outgrowth in PC12 cells by the medium-chain fatty acid octanoic acid","volume":"146","author":"Kamata","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejmech.2018.01.037_bib58","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1021\/jm010268g","article-title":"A\u00a0prodrug form of a plasmodium falciparum glutathione reductase inhibitor conjugated with a 4-anilinoquinoline","volume":"44","author":"Davioud-Charvet","year":"2001","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.037_bib59","doi-asserted-by":"crossref","first-page":"4661","DOI":"10.1016\/j.bmc.2010.05.025","article-title":"[d4U]-Spacer-[HI-236] double-drug inhibitors of HIV-1 reverse-transcriptase","volume":"18","author":"Younis","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.037_bib60","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1021\/bc900176a","article-title":"A\u00a0Wortmannin\u2212Cetuximab as a double drug","volume":"20","author":"Smith","year":"2009","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.ejmech.2018.01.037_bib61","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1523\/JNEUROSCI.22-06-02174.2002","article-title":"The mitochondrial toxin 3-nitropropionic acid induces striatal neurodegeneration via a c-Jun N-terminal kinase\/c-Jun module","volume":"22","author":"Garcia","year":"2002","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ejmech.2018.01.037_bib62","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1046\/j.1471-4159.1998.70020794.x","article-title":"Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in rat","volume":"70","author":"Brouillet","year":"1998","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ejmech.2018.01.037_bib63","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/j.1471-4159.2005.03515.x","article-title":"3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease","volume":"95","author":"Brouillet","year":"2005","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ejmech.2018.01.037_bib64","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1084\/jem.20080178","article-title":"A\u00a0novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease","volume":"205","author":"Bjorkqvist","year":"2008","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ejmech.2018.01.037_bib65","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.bbi.2014.09.011","article-title":"Plasma inflammatory biomarkers for Huntington's disease patients and mouse model","volume":"44","author":"Chang","year":"2015","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.ejmech.2018.01.037_bib66","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1523\/JNEUROSCI.13-10-04181.1993","article-title":"Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid","volume":"13","author":"Beal","year":"1993","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ejmech.2018.01.037_bib67","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.neuro.2014.10.004","article-title":"Potential of protease inhibitor in 3-nitropropionic acid induced Huntington's disease like symptoms: mitochondrial dysfunction and neurodegeneration","volume":"45","author":"Hariharan","year":"2014","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.ejmech.2018.01.037_bib68","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0149-7634(96)00027-9","article-title":"3-Nitropropionic acid animal model and Huntington's disease","volume":"21","author":"Borlongan","year":"1997","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.ejmech.2018.01.037_bib69","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S0006-8993(00)01948-X","article-title":"3-nitropropionic acid induced in\u00a0vivo protein oxidation in striatal and cortical synaptosomes: insights into Huntington's disease","volume":"858","author":"La Fontaine","year":"2000","journal-title":"Brain Res."},{"key":"10.1016\/j.ejmech.2018.01.037_bib70","doi-asserted-by":"crossref","first-page":"16933","DOI":"10.3390\/molecules200916933","article-title":"Synthesis and biological evaluation of resveratrol derivatives as melanogenesis inhibitors","volume":"20","author":"Liu","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2018.01.037_bib71","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1016\/S0040-4020(03)00405-8","article-title":"A\u00a0re-investigation of resveratrol synthesis by Perkins reaction. Application to the synthesis of aryl cinnamic acids","volume":"59","author":"Solladi\u00e9","year":"2003","journal-title":"Tetrahedron"},{"key":"10.1016\/j.ejmech.2018.01.037_bib72","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1080\/07328301003597673","article-title":"N-Aryl-O-glycosyl haloacetimidates as glycosyl donors","volume":"29","author":"Huchel","year":"2010","journal-title":"J.\u00a0Carbohydr. Chem."},{"key":"10.1016\/j.ejmech.2018.01.037_bib73","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1002\/anie.200351534","article-title":"A\u00a0programmable one-pot oligosaccharide synthesis for diversifying the sugar domains of natural products: a case study of vancomycin","volume":"42","author":"Ritter","year":"2003","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2018.01.037_bib74","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/0031-9422(94)00915-G","article-title":"Stilbene glycosides from Guibourtia tessmannii","volume":"39","author":"Nyemba","year":"1995","journal-title":"Phytochemistry"},{"issue":"3","key":"10.1016\/j.ejmech.2018.01.037_bib75","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10600-009-9352-8","article-title":"A\u00a0new stilbene glycoside from the n-butanol fraction of Veratrum dahuricum","volume":"45","author":"Dai","year":"2009","journal-title":"Chem. Nat. Compd."},{"key":"10.1016\/j.ejmech.2018.01.037_bib76","doi-asserted-by":"crossref","first-page":"9140","DOI":"10.1021\/jf801988p","article-title":"Algicidal activity of stilbene analogues","volume":"56","author":"Mizuno","year":"2008","journal-title":"J.\u00a0Agric. Food Chem."},{"key":"10.1016\/j.ejmech.2018.01.037_bib77","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/gut.2008.168534","article-title":"Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis","volume":"58","author":"Gonzalez-Rey","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.ejmech.2018.01.037_bib78","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jpba.2011.03.029","article-title":"Strategy to confirm the presence of anti-erythropoietin neutralizing antibodies in human serum","volume":"55","author":"Sanchez","year":"2011","journal-title":"J\u00a0Pharm Biomed Anal"},{"key":"10.1016\/j.ejmech.2018.01.037_bib79","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0006-2952(61)90145-9","article-title":"A\u00a0new and rapid colorimetric determination of acetylcholinesterase activity","volume":"7","author":"Ellman","year":"1961","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.01.037_bib80","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1111\/j.0953-816X.2004.03372.x","article-title":"Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease","volume":"19","author":"Diguet","year":"2004","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejmech.2018.01.037_bib81","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.neuropharm.2012.05.019","article-title":"Activating mitochondrial regulator PGC-1alpha expression by astrocytic NGF is a therapeutic strategy for Huntington's disease","volume":"63","author":"Chen","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2018.01.037_bib82","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0306-4522(02)00205-1","article-title":"Subacute systemic 3-nitropropionic acid intoxication induces a distinct motor disorder in adult C57Bl\/6 mice: behavioural and histopathological characterisation","volume":"114","author":"Fernagut","year":"2002","journal-title":"Neuroscience"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418300503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418300503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T17:54:54Z","timestamp":1751219694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523418300503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":82,"alternative-id":["S0223523418300503"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.01.037","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alkylated resveratrol prodrugs and metabolites as potential therapeutics for neurodegenerative diseases","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.01.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}